<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799292</url>
  </required_header>
  <id_info>
    <org_study_id>ASW 123</org_study_id>
    <nct_id>NCT00799292</nct_id>
  </id_info>
  <brief_title>Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial</brief_title>
  <official_title>Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascher-Walsh, Charles, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascher-Walsh, Charles, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoconstrictive agents are increasingly being used in order to decrease blood loss during
      vaginal hysterectomy. The first reported study of the use of a vasoconstrictive agent for
      this purpose was on the use of epinephrine injected intracervically preoperatively by
      England, et. al. They demonstrated a significant decrease in the amount of blood lost during
      the surgery but also demonstrated a significant increase in the risk of post-operative
      infections, most frequently a vaginal cuff cellulitis requiring antibiotic treatment. Recent
      studies using vasopressin as the vasoconstrictive agent have also found the same significant
      decrease in blood loss while not demonstrating a difference in the rate of post-operative
      infections. The more recent studies by Speer and Unger , and Kammerer-Doak, et.al. were
      larger, better designed studies and are considered more credible. More surgeons are therefore
      injecting vasopressin intracervically preoperatively.

      Some surgeons believe that the injection of vasopressin intracervically prior to the initial
      incision of a vaginal hysterectomy effects surgical plains and therefore makes the surgical
      dissection more difficult. This is thought to possibly both add to operative time and
      increase the rate of complications. The aforementioned studies used the injection of saline
      as a control for the injection of vasopressin or epinephrine. To date, no study has compared
      the use of vasopressin versus no injection in a controlled, randomized manner. We do not know
      if the injection of saline intracervically may actually increase the amount of bleeding over
      the baseline and therefore the decreased blood loss caused by the injection of vasopressin my
      actually be overestimated.

      We propose to compare the effects of injecting vasopressin intracervically preoperatively
      versus no preoperative medication. We will not only evaluate the amount of operative blood
      loss, but also compare operative time and complication rates.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-Operative Blood Loss During Vaginal Hysterectomy</measure>
    <time_frame>Blood loss will be assessed at the end of the operative procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>Duration of vaginal hysterectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative Time and Complication Rates</measure>
    <time_frame>Duration of procedures and immediate post-operative stay in hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Blood Loss During Vaginal Hysterectomy</condition>
  <arm_group>
    <arm_group_label>No injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients did not receive an injection at cervix prior to beginning the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection of vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix</description>
    <arm_group_label>Injection of vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No injection</intervention_name>
    <description>Patients did not receive an injection of medication at cervix prior to beginning of procedure</description>
    <arm_group_label>No injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women greater that 18 undergoing vaginal hysterectomy for any indication, with or
             without concomitant procedures

        Exclusion Criteria:

          -  women with a significant medical condition, including severe liver disease, congestive
             heart failure, documented coronary artery disease, impaired renal function determined
             by an elevated serum creatinine, asthma with steroid use in the past year, and
             migraines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Ascher-Walsh, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt Sinai School of Medicine, Dept Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2008</study_first_posted>
  <results_first_submitted>October 21, 2008</results_first_submitted>
  <results_first_submitted_qc>November 26, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2008</results_first_posted>
  <last_update_submitted>November 26, 2008</last_update_submitted>
  <last_update_submitted_qc>November 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Charles Ascher-Walsh MD, MPH</name_title>
    <organization>Mt Sinai School of Medicine, Department of Obstetrics and Gynecology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment and informed consent was obtained prior to the operation in the gynecology clinic or private offices from 1/2004 - 1/2005.</recruitment_details>
      <pre_assignment_details>Randomization occurred at the time of surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Injection</title>
          <description>Patients did not receive an injection at cervix prior to beginning the procedure.</description>
        </group>
        <group group_id="P2">
          <title>Injection of Vasopressin</title>
          <description>Patients will be randomized to receive 20cc of dilute vasopressin (20 units in 50cc normal saline) injected at cervix at beginning of the hysterectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Injection</title>
          <description>Patients did not receive an injection at cervix prior to beginning the procedure.</description>
        </group>
        <group group_id="B2">
          <title>Injection of Vasopressin</title>
          <description>Patients will be randomized to receive 20cc of dilute vasopressin (20 units in 50cc normal saline) injected at cervix at beginning of the hysterectomy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intra-operative Blood Loss During Vaginal Hysterectomy</title>
        <time_frame>Blood loss will be assessed at the end of the operative procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Time and Complication Rates</title>
        <time_frame>Duration of procedures and immediate post-operative stay in hospital</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated Blood Loss</title>
        <description>Estimated blood loss as mL</description>
        <time_frame>Duration of vaginal hysterectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Injection</title>
            <description>Patients did not receive an injection at cervix prior to beginning the procedure.</description>
          </group>
          <group group_id="O2">
            <title>Injection of Vasopressin</title>
            <description>Patients will be randomized to receive 20cc of dilute vasopressin (20 units in 50cc normal saline) injected at cervix at beginning of the hysterectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Blood Loss</title>
          <description>Estimated blood loss as mL</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.4" spread="240.50"/>
                    <measurement group_id="O2" value="145.3" spread="137.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Ascher-Walsh MD, MPH</name_or_title>
      <organization>Mt Sinai School of Medicine, Department of Obstetrics and Gynecology</organization>
      <phone>212-241-2827</phone>
      <email>charles.ascher-walsh@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

